Zhengye Biotechnology Holding (ZYBT) Liabilities and Shareholders Equity (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $61.5 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 10.38% year-over-year to $61.5 million in Q4 2025; TTM through Dec 2025 was $269.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $61.5 million, down 10.38% from the prior year.
• Liabilities and Shareholders Equity was $61.5 million for Q4 2025 at Zhengye Biotechnology Holding, down from $69.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $69.8 million in Q2 2025 and troughed at $61.5 million in Q4 2025.
• A 3-year average of $67.4 million and a median of $69.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity dropped 1.1% in 2024 and slipped 10.38% in 2025, its largest moves.
• Over 3 years, Liabilities and Shareholders Equity stood at $69.4 million in 2023, then retreated by 1.1% to $68.7 million in 2024, then dropped by 10.38% to $61.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $61.5 million (Q4 2025), $69.8 million (Q2 2025), and $68.7 million (Q4 2024), per Business Quant data.